CoQ10 and D-ribose in Patients With Diastolic Heart Failure
| Status: | Recruiting |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 50 - Any |
| Updated: | 4/6/2019 |
| Start Date: | February 5, 2018 |
| End Date: | March 2021 |
| Contact: | Faith Rahman |
| Email: | frahman2@kumc.edu |
| Phone: | (913) 588-4336 |
Reducing Symptom Burden in Patients With Heart Failure With Preserved Ejection Fraction Using Ubiquinol and/or D-ribose
The purpose of this study is to compare the clinical benefits of CoQ10 and D-ribose taken by
patients who have diastolic heart failure, or heart failure with preserved ejection fraction
(HFpEF).
patients who have diastolic heart failure, or heart failure with preserved ejection fraction
(HFpEF).
Inclusion Criteria:
- Diagnosed with HFpEF within a 6-month period
- New York Heart Association (NYHA) Classification II-III HF
- Have left ventricular ejection fraction (EF) ≥ 50% documented by an echocardiogram
- Have a telephone or reliable phone contact
- Have their own means of transportation to the study site
Exclusion Criteria:
- Acute coronary syndrome in the past 12 weeks
- Significant valvular heart disease
- Severe cardiac fibrosis (galectin-3 level > 26 ng/ml)
- Constrictive pericardium
- Pulmonary fibrosis
- Congenital heart disease
- Hypertrophic or infiltrative cardiomyopathy
- Heart transplant
- Left ventricular assist device
- Heart failure (HF) associated hospital admission or emergency room visit within past
30 days
- Recent percutaneous coronary intervention
- Significant renal and/or hepatic dysfunction
- Severe cognitive impairment
- Consumption of any CoQ10 (ubiquinol) or D-ribose supplements
We found this trial at
1
site
University of Kansas Medical Center The University of Kansas Medical Center serves Kansas through excellence...
Click here to add this to my saved trials
